San Diego — Nemolizumab, the first-in-class inhibitor of interleukin-31 (IL-31), a neuroimmune cytokine linked to the promotion of pruritis and inflammation, continues to show good efficacy and safety ...

Few validated measures exist to quantify sleep disturbance among patients who have the chronic inflammatory skin condition prurigo nodularis. SD NRS scoring ranges from 0 (no sleep loss) to 10 (no ...

NEW ORLEANS -- An investigational antibody targeting interleukin (IL)-31 in prurigo nodularis significantly reduced itch, skin lesions, and sleep disturbance in a phase III trial. More than half of ...

The FDA has granted nemolizumab Priority Review for the treatment of prurigo nodularis. The Food and Drug Administration (FDA) has accepted for review the Biologics License Applications (BLA) for ...

Nemolizumab (Mitchga) is gearing up to be a potential new treatment for prurigo nodularis, with further phase 3 data supporting its efficacy and safety reported this month at the annual meeting of the ...

Sanofi SNY and partner Regeneron REGN announced that the European Commission (EC) approved their blockbuster medicine Dupixent (dupilumab) for the treatment of adult patients with moderate-to-severe ...

Please provide your email address to receive an email when new articles are posted on . Prurigo nodularis prevalence was 0.19% which is higher than previous estimates of 0.02% to 0.07%. Older ...

SAN DIEGO -- More than two-thirds of patients with prurigo nodularis obtained long-term relief from itching, skin lesions, and sleep disturbance with the interleukin (IL)-31 antagonist nemolizumab, ...